Breaking News

Kashiv BioSciences & JAMP Pharma Launch Biosimilars in Canada

Pexegra and Filra will be available with support from JAMP’s commercialization efforts in Canada.

By: Rachel Klemovitch

Assistant Editor

Kashiv BioSciences commercially launched Pexegra, a biosimilar referencing Neulasta, and Filra, a biosimilar referencing Neupogen, in the Canadian market.  Pexegra and Filra biosimilars will be marketed in Canada through an exclusive agreement with JAMP Pharma Corporation. Exegra (6 mg/0.6 mL pre-filled syringe) and Filra (300 mcg/0.5 mL and 480 mcg/0.8 mL pre-filled syringe) are used to treat neutropenia, low neutrophils, which are a type of white blood cell that fight infection, which is...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters